Haiming Luo1, Christopher G England2, Stephen A Graves2, Haiyan Sun1, Glenn Liu3, Robert J Nickles2, Weibo Cai4. 1. Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin. 2. Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin; and. 3. University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. 4. Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin; and University of Wisconsin Carbone Cancer Center, Madison, Wisconsin wcai@uwhealth.org.
Abstract
UNLABELLED: Lung cancer accounts for 17% of cancer-related deaths worldwide, and most patients present with locally advanced or metastatic disease. Novel PET imaging agents for assessing vascular endothelial growth factor receptor-2 (VEGFR-2) expression can be used for detecting VEGFR-2-positive malignancies and subsequent monitoring of therapeutic response to VEGFR-2-targeted therapies. Here, we report the synthesis and characterization of an antibody-based imaging agent for PET imaging of VEGFR-2 expression in vivo. METHODS: Ramucirumab (named RamAb), a fully humanized IgG1 monoclonal antibody, was conjugated to 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) and labeled with (64)Cu. Flow cytometry analysis and microscopy studies were performed to compare the VEGFR-2 binding affinity of RamAb and NOTA-RamAb. PET imaging and biodistribution studies were performed in nude mice bearing HCC4006 and A549 xenograft tumors. Ex vivo histopathology was performed to elucidate the expression patterns of VEGFR-2 in different tissues and organs to validate in vivo results. RESULTS: Flow cytometry examination revealed the specific binding capacity of fluorescein isothiocyanate-RamAb to VEGFR-2, and no difference in VEGFR-2 binding affinity was seen between RamAb and NOTA-RamAb. After being labeled with (64)Cu, PET imaging revealed specific and prominent uptake of (64)Cu-NOTA-RamAb in VEGFR-2-positive HCC4006 tumors (9.4 ± 0.5 percentage injected dose per gram at 48 h after injection; n = 4) and significantly lower uptake in VEGFR-2-negative A549 tumors (4.3 ± 0.2 percentage injected dose per gram at 48 h after injection; n = 3). Blocking experiments revealed significantly lower uptake in HCC4006 tumors, along with histology analysis, further confirming the VEGFR-2 specificity of (64)Cu-NOTA-RamAb. CONCLUSION: This study provides initial evidence that (64)Cu-NOTA-RamAb can function as a PET imaging agent for visualizing VEGFR-2 expression in vivo, which may also find potential applications in monitoring the treatment response of VEGFR-2-targeted cancer therapy.
UNLABELLED: Lung cancer accounts for 17% of cancer-related deaths worldwide, and most patients present with locally advanced or metastatic disease. Novel PET imaging agents for assessing vascular endothelial growth factor receptor-2 (VEGFR-2) expression can be used for detecting VEGFR-2-positive malignancies and subsequent monitoring of therapeutic response to VEGFR-2-targeted therapies. Here, we report the synthesis and characterization of an antibody-based imaging agent for PET imaging of VEGFR-2 expression in vivo. METHODS:Ramucirumab (named RamAb), a fully humanized IgG1 monoclonal antibody, was conjugated to 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) and labeled with (64)Cu. Flow cytometry analysis and microscopy studies were performed to compare the VEGFR-2 binding affinity of RamAb and NOTA-RamAb. PET imaging and biodistribution studies were performed in nude mice bearing HCC4006 and A549 xenograft tumors. Ex vivo histopathology was performed to elucidate the expression patterns of VEGFR-2 in different tissues and organs to validate in vivo results. RESULTS: Flow cytometry examination revealed the specific binding capacity of fluorescein isothiocyanate-RamAb to VEGFR-2, and no difference in VEGFR-2 binding affinity was seen between RamAb and NOTA-RamAb. After being labeled with (64)Cu, PET imaging revealed specific and prominent uptake of (64)Cu-NOTA-RamAb in VEGFR-2-positive HCC4006 tumors (9.4 ± 0.5 percentage injected dose per gram at 48 h after injection; n = 4) and significantly lower uptake in VEGFR-2-negative A549 tumors (4.3 ± 0.2 percentage injected dose per gram at 48 h after injection; n = 3). Blocking experiments revealed significantly lower uptake in HCC4006 tumors, along with histology analysis, further confirming the VEGFR-2 specificity of (64)Cu-NOTA-RamAb. CONCLUSION: This study provides initial evidence that (64)Cu-NOTA-RamAb can function as a PET imaging agent for visualizing VEGFR-2 expression in vivo, which may also find potential applications in monitoring the treatment response of VEGFR-2-targeted cancer therapy.
Authors: Jenny Yao; Xiumin Wu; Guanglei Zhuang; Ian M Kasman; Tobias Vogt; Vernon Phan; Masabumi Shibuya; Napoleone Ferrara; Carlos Bais Journal: Proc Natl Acad Sci U S A Date: 2011-06-27 Impact factor: 11.205
Authors: Jürgen K Willmann; Ramasamy Paulmurugan; Kai Chen; Olivier Gheysens; Martin Rodriguez-Porcel; Amelie M Lutz; Ian Y Chen; Xiaoyuan Chen; Sanjiv S Gambhir Journal: Radiology Date: 2008-01-07 Impact factor: 11.105
Authors: Melissa J Cudmore; Peter W Hewett; Shakil Ahmad; Ke-Qing Wang; Meng Cai; Bahjat Al-Ani; Takeshi Fujisawa; Bin Ma; Samir Sissaoui; Wenda Ramma; Mark R Miller; David E Newby; Yuchun Gu; Bernhard Barleon; Herbert Weich; Asif Ahmed Journal: Nat Commun Date: 2012-07-24 Impact factor: 14.919
Authors: Haiyan Sun; Christopher G England; Reinier Hernandez; Stephen A Graves; Rebecca L Majewski; Anyanee Kamkaew; Dawei Jiang; Todd E Barnhart; Yunan Yang; Weibo Cai Journal: Eur J Nucl Med Mol Imaging Date: 2016-06-25 Impact factor: 9.236
Authors: Miao Li; Dawei Jiang; Todd E Barnhart; Tianye Cao; Jonathan W Engle; Weiyu Chen; Weibo Cai Journal: Am J Cancer Res Date: 2019-09-01 Impact factor: 6.166
Authors: Bogdan Mitran; Rezan Güler; Francis P Roche; Elin Lindström; Ram Kumar Selvaraju; Filippa Fleetwood; Sara S Rinne; Lena Claesson-Welsh; Vladimir Tolmachev; Stefan Ståhl; Anna Orlova; John Löfblom Journal: Theranostics Date: 2018-08-07 Impact factor: 11.556
Authors: T Tegnebratt; L Lu; S Eksborg; A Chireh; P Damberg; S Nikkhou-Aski; T Foukakis; H Rundqvist; S Holmin; R V Kuiper; E Samen Journal: EJNMMI Res Date: 2018-04-03 Impact factor: 3.138